Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL

Biochemical and Biophysical Research Communications

Volumn 344, Issue 4, 2006, Pages 1271-1277

  Rosenblat, Mira ^a   Oren, Roni ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

LDL oxidation; Lysophosphatidylcholine (LPC); Macrophages; NADPH oxidase; Paraoxonase 2 (PON2)

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 2; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHORBOL ESTER; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; FOAM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LIPID ANALYSIS; LIPID OXIDATION; MACROPHAGE FUNCTION; MONOCYTE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CELL MEMBRANE; CYTOPLASM; HUMANS; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; NADPH OXIDASE; OXIDATION-REDUCTION; PHORBOL ESTERS; SUPEROXIDES;

EID: 33646192659     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.038     Document Type: Article

References (48)

1. 2 in atherosclerosis. Biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 923-931
2. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., and Aviram M. Paraoxonase 1 (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34 (2003) 774-784
3. Rosenblat M., Vaya J., Shih D.M., and Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179 (2005) 69-77
4. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7649-7656
5. Thukkani A.K., MeHowat J., Hsu F.F., Brennan M.L., Hazen S.L., and Ford D.A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108 (2003) 3128-3133
6. Kume N., Cybulsky M.I., and Gimbrone Jr. M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90 (1992) 1138-1144
7. Takahara N., Kashiwagi A., Maegawa H., and Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 45 (1996) 559-564
8. Rong J.X., Berman J.W., Taubman M.B., and Fisher E.A. Lysophosphatidylcholine stimulates monocytes chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1617-1623
9. Chai Y.C., Howe P.H., DiCorleto P.E., and Chisolm G.M. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for the release of fibroblast growth factor-2. J. Biol. Chem. 271 (1996) 17791-17797
10. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Hanehira T., and Yoshikawa J. Induction by lysophosphatidylcholine, a major phospholipids component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98 (1998) 353-359
11. Yan S., Chai H., Wang H., Yang H., Nan B., Yao Q., and Chen C. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 138 (2005) 464-473
12. Matsubara M., Yao K., and Hasegawa K. Benidipine, a dihdropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharmacol. Res. 53 (2006) 35-46
13. Hsieh C.C., Yen M.H., Liu H.W., and Lau Y.T. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 151 (2000) 481-491
14. Colles S.M., and Chisolm G.M. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J. Lipid Res. 41 (2000) 1188-1198
15. Wong J.T., Tran K., Pierce G.N., Chan A.C., and Chy P.C. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J. Biol. Chem. 273 (1998) 6830-6836
16. Celan A., Karasu C., Aktan F., and Ozansoy G. Simvastatin treatment restores vasoconstriction and the inhibitory effect of LPC on endothelial relaxation via affecting oxidizing metabolism in diabetic rats. Diabetes Nutr. Metab. 17 (2004) 203-210
17. Lusis A.J. Atherosclerosis. Nature (2000) 233-241
18. Oka H., Kugiyama K., Doi H., Matsumura T., Shibata H., Miles L.A., Sugiyama S., and Yasue H. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 244-250
19. Liu-Wu Y., Hurt-Camejo E., and Wiklund O. Lysophosphatidylcholine induces the production of IL-1 beta by human monocytes. Arteriosclerosis 137 (1998) 351-357
20. Oestvang J., Anthonsen M.W., and Johansen B. Role of secretory and cytosolic phospholipase A2 enzymes in lysophosphatidylcholine-stimulated monocytes arachidonic acid release. FEBS Lett. 555 (2003) 257-262
21. Kita T., Kume N., Yokode M., Ishii K., Arai H., Horiuchi H., Moriwaki H., Minami M., Kataoka H., and Wakatsuki Y. Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann. N. Y. Acad. Sci. 902 (2000) 95-100
22. Ousman S.S., and David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 30 (2000) 92-104
23. Rozenberg O., Shih D.M., and Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 461-467
24. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
25. Masayuki Y., Hirokazu H., and Tetsuo A. The expression of extracellular-superoxide dismutase is increased by lysophosphatidylcholine in human monocytic U937 cells. Atherosclerosis 163 (2002) 223-228
26. Lin P., Welch E.J., Gao X.P., Malik A.B., and Ye R.D. Lysophosphatidylcholine modulates neutrophils oxidant production through elevation of cyclic AMP. J. Immunol. 174 (2005) 2981-2989
27. Kabarowski J.H.S., Xu Y., and Witte O.N. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem. Pharmacol. 64 (2002) 161-167
28. Irritate Y., Hirata K.I., Yamashita T., Iwai K., Kobayashi S., Itoh H., Ozaki M., Ejiri J., Shiomi M., Inoue N., Kawashima S., and Yokoyama M. Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 2049-2053
29. Aviram M., Rosenblat M., Etzioni A., and Levy R. Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein. Metabolism 45 (1996) 1064-1078
30. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
31. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hypercholesterolemic patients. Biochem. Med. 30 (1983) 111-118
32. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52 (1978) 302-310
33. Rosenblat M., Draganov D., Watson C.E., Bisgaier C.L., La Du B.N., and Aviram M. Mouse macrophage paraoxonase 2 (PON2) activity is increased whereas cellular PON3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 468-474
34. Yokoyama M., Inoue N., and Kawashima S. Role of the vascular NADH/NADPH oxidase system in atherosclerosis. Ann. N. Y. Acad. Sci. 902 (2000) 241-247
35. Cathcart M.K. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 23-28
36. Durrington P.N., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
37. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., and Fogelman A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 542-547
38. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
39. Fuhrman B., Shiner M., Volkova N., and Aviram M. Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-to-macrophage differentiation. Free Radic. Biol. Med. 37 (2004) 259-271
40. Chen K., Thomas S.R., and Keaney Jr. J.F. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic. Biol. Med. 35 (2003) 117-132
41. Napoli C., de Nigris F., and Palinski W. Multiple role of reactive oxygen species in the arterial wall. J. Cell. Biochem. 82 (2001) 674-682
42. Terasawa K., Nakajima T., Iida H., Iwasawa K., Oonuma H., Jo T., Morita ., Nakamura F., Fujimori Y., Toyo-oka T., and Nagai R. Nonselective cation currents regulate membrane potential of rabbit coronary arterial cell: modulation by lysophosphatidylcholine. Circulation 106 (2002) 3111-3119
43. Brandes R.P., Miller F.J., Beer S., Haendeler J., Hoffmann J., Ha T., Holland S.M., Gorlach A., and Buss R. The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic. Biol. Med. 32 (2002) 1116-1122
44. Bey E.A., and Cathcart M.K. In vitro knockout of human p47phox blocks superoxide anion production and LDL oxidation by activated human monocytes. J. Lipid Res. 41 (2000) 489-495
45. Kuo C.L., and La Du B.N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23 (1995) 935-944
46. 31P-NMR. J. Lipid Res. 42 (2001) 1501-1508
47. Duong C.Q., Bared S.M., Abu-Khader A., Buechler C., Schmitz A., and Schmitz G. Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim. Biophys. Acta 1682 (2004) 112-119
48. Wang L., Radu C.G., Yang L.V., Bentolila L.A., Riedinger M., and Witte O.N. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G-protein-coupled receptor G2A. Mol. Biol. Cell. 16 (2005) 2234-2247